Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.

The Kaohsiung journal of medical sciences - 1 Nov 2017

Huang Jee-Fu, Huang Chung-Feng, Yeh Ming-Lun, Dai Chia-Yen, Hsieh Meng-Hsuan, Yang Jeng-Fu, Huang Ching-I, Lin Yi-Hung, Liang Po-Cheng, Lin Zu-Yau, Chen Shinn-Chern, Yu Ming-Lung, Chuang Wan-Long

Abstract excerpt

Direct-acting antiviral agents (DAAs) have been widely used for chronic hepatitis C (CHC) treatment recently. The characteristics of glucose abnormalities after DAAs therapy however, remain elusive. We aimed to elucidate the mutual impact between treatment response and parameters of glucose abnormalities after DAAs therapy in CHC patients. CHC patients who received DAAs therapy were recruited. The primary outcome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Naphthylamine
Share to Anilides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoquinolines

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Pyrrolidines

Share to Ritonavir

Share to Uracil

Source

Identifiers

PMID: 29050674
DOI: 10.1016/j.kjms.2017.07.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.PMID 29050674Read ↗

Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.Semantic proximity Read ↗

Metabolic changes in chronic hepatitis C patients receiving direct acting antiviralsSemantic proximity Read ↗

Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.Semantic proximity Read ↗

The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy.Semantic proximity Read ↗

Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.Semantic proximity Read ↗

Effects of hepatitis C virus genotypes and viral load on glucose and lipid metabolism after sustained virological response with direct-acting antivirals.Semantic proximity Read ↗

Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.Semantic proximity Read ↗

Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment.Semantic proximity Read ↗

Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.Semantic proximity Read ↗

Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.